Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
Tom EwenAkhtar HusainNiki StefanosPaul BarrettClaire JonesTom NessAnna LongStuart HorswellHelen BosomworthJoe LowensteinGrant RichardsonDavid SwanAshleigh McConnellAidan RoseTom AndrewNick ReynoldsJosep MalvehyChristina CarreraLlucia AlsoSonia MailerTom HelmLiang DingPaul BognerSebastian PodlipnikSusana Puig SardàGrant A McArthurGyorgy ParaghMarie LabusPhilip SloanJane L ArmstrongPenny E LovatPublished in: The British journal of dermatology (2023)
These data provide further evidence validating AMBLor as a prognostic biomarker to identify non-ulcerated AJCC stage I and II melanoma tumours at low risk of disease recurrence.